Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
about
Liver transplantation in glycogen storage disease type ISLC transporters as therapeutic targets: emerging opportunitiesDownregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia.Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-α deficiencyPreclinical Development of New Therapy for Glycogen Storage Diseases.Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.Minimal hepatic glucose-6-phosphatase-α activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia.In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes.Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics.Periodontal and other oral manifestations of immunodeficiency diseases.Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy.Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.Liver-directed gene therapy for murine glycogen storage disease type Ib.Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice.Adeno-associated virus gene therapy prevents hepatocellular adenoma in murine model of glycogen storage disease type Ia.No tumour-initiating risk associated with scAAV transduction in newborn rat liver.Current status of hepatic glycogen storage disease in Japan: clinical manifestations, treatments and long-term outcomes.Hepatic glucose-6-phosphatase-α deficiency leads to metabolic reprogramming in glycogen storage disease type Ia.The Physiopathological Role of the Exchangers Belonging to the SLC37 Family.
P2860
Q27013712-5E45F6D9-3FEB-40DE-B6F0-FD629F1548C2Q27014726-CBD2B70C-D040-4303-9A89-6CB850935C2CQ33793256-25C705D5-3026-440B-817B-CE07737D6352Q34081768-A7268CA2-4613-4A3E-BAFD-93A26542F2CBQ35677604-EFC1C1F6-8804-4353-B79B-42D43A16010AQ35999250-B5D55D0D-5C24-4CCD-BA67-AA8C47F595C8Q36571603-4CE03F0D-6486-4AF4-A724-1A02BBD857A1Q36951279-3087AF48-FC5C-460D-B434-8F87A36610CCQ37503995-44B61B08-89BE-462E-910D-95A00F9E499DQ38257397-41B77C8F-4BB1-49A8-B93E-20B4EBAF80B1Q38263927-682F7A21-4DE9-43BE-A24E-BCCEABE6FAD1Q38954801-D820AE62-3DB0-47B9-96D6-08A3C9BF7AA7Q40277667-7C668D3F-0C7E-425D-9B07-AC2156C0B644Q40376931-82C915CA-A1EF-4168-ABE4-12EC48B9CA9AQ41925391-AE7F9E49-FE7A-4419-A071-45F2733E479DQ42175592-69A2D1EB-49B8-488B-B417-CCE547258AB5Q44478940-8C55D93C-155A-4795-B8AD-5DF9C684727EQ45790615-E074DB75-1D87-4438-9597-86849F0C6C06Q46210619-00B25BD5-182D-485D-A196-16EB3F39999FQ52726308-A14ABFFF-A8C7-4F3F-8502-C90AAE266F19Q55032191-4DB03FAC-D2E2-4C0C-875A-8F535CA16CAD
P2860
Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Prevention of hepatocellular a ...... sease type Ia by gene therapy.
@ast
Prevention of hepatocellular a ...... sease type Ia by gene therapy.
@en
type
label
Prevention of hepatocellular a ...... sease type Ia by gene therapy.
@ast
Prevention of hepatocellular a ...... sease type Ia by gene therapy.
@en
prefLabel
Prevention of hepatocellular a ...... sease type Ia by gene therapy.
@ast
Prevention of hepatocellular a ...... sease type Ia by gene therapy.
@en
P2093
P2860
P356
P1433
P1476
Prevention of hepatocellular a ...... sease type Ia by gene therapy.
@en
P2093
Brian C Mansfield
Chi-Jiunn Pan
Hyun Sik Jun
Janice Y Chou
Lane H Wilson
Young Mok Lee
P2860
P304
P356
10.1002/HEP.25717
P407
P577
2012-08-27T00:00:00Z